Fairmount Healthcare Fund II L.P. Buys $20M in Viridian Therapeutics Stock
VRDN sits 51% above its 52-week low of $12.07.
Summary
Fairmount Healthcare Fund II L.P., a 10% owner and director-affiliated entity, made a $20 million open market purchase of Viridian Therapeutics common stock, significantly increasing its stake.
Key Events · Ownership and Investor Activity · VRDN
-
Significant Insider Purchase
Fairmount Healthcare Fund II L.P. acquired 1,176,470 shares of common stock for $19,999,990 at a price of $17.00 per share on May 11, 2026.
-
Increased Institutional Stake
This purchase by a 10% owner and director-affiliated entity represents a substantial increase in its holdings, demonstrating strong conviction in the company's prospects.
-
Post-Offering Investment
The transaction occurred after recent public offerings and positive clinical trial results, but also following a stock decline due to competitor news, indicating a strategic investment at this juncture.
Analysis · VRDN · Life Sciences
This substantial open market purchase by Fairmount Healthcare Fund II L.P., a 10% owner and entity with board representation, signals strong conviction in Viridian Therapeutics. The $20 million investment, representing over 1% of the company's market capitalization, occurred shortly after the company announced positive Phase 3 data for elegrobart and concurrent public offerings, but also after a significant stock drop due to competitor news. This purchase demonstrates a significant vote of confidence from a key institutional investor.
At the time of this filing, VRDN was trading at $18.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $12.07 to $34.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.